hydromorphone once daily (CEP-33236) / Teva - LARVOL DELTA

Comparing oral hydromorphone hydrochloride sustained-release tablets versus morphine hydrochloride sustained-release tablets for moderate to severe cancer pain after successful Subcutaneous Patient-Controlled Analgesia titration with hydromorphone hydrochloride injection, A randomized, controlled, multicenter clinical study (ChiCTR) - P=N/A | N=236 | Sponsor: Affiliated Cancer Hospital of Chongqing University; Affiliated Cancer Hospital of Chongqing University

New trial • Oncology • Pain

Reduction in Substance Use-Related Harms Among a Cohort of People Receiving Injectable Opioid Agonist Treatment in Ontario, Canada (CPDD 2023) - "In Ontario, Canada, an iOAT program run by The Works (Toronto Public Health) was established in 2021, and dispenses daily witnessed injectable hydromorphone with overnight slow-release oral morphine or methadone...We also compared daily fentanyl and heroin injection frequencies at baseline and follow-up... In a preliminary assessment, PWID receiving iOAT had significantly fewer overdose events and less unregulated opioid injection over time. Future real-world implementation experiences of iOAT with larger sample sizes and control groups are needed to characterize the potential impacts of this modality in the synthetic opioid era. 1"

Addiction (Opioid and Alcohol) • Substance Abuse

Cannabinoid Hyperemesis Syndrome Complicated by Pneumomediastinum: Implications for Pediatric Surgeons. (PubMed, Clin Surg J) - "CHS in an increasingly common disorder encountered in the pediatric setting due to rising prevalence of cannabis use. The management of CHS and potentially life-threatening complications such as pneumomediastinum should be given careful consideration. Pneumomediastinum can be a harbinger of more sinister pathology such as esophageal perforation, which may warrant urgent surgical intervention."

Journal • Back Pain • Gastrointestinal Disorder • Musculoskeletal Pain • Pain • Pediatrics • Rare Diseases

Sustained-release Oral Hydromorphone for the Treatment of Opioid Use Disorder. (PubMed, J Addict Med) - "The case presented offers promise for the use of once-daily sustained-release oral hydromorphone as a viable treatment option for patients with OUD for whom first-line therapies are not suitable or tolerated. This case report is the first to our knowledge to demonstrate the successful use of oral hydromorphone for treatment of opioid use disorder."

Journal

Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients (clinicaltrials.gov) - P3; N=4; Terminated; Sponsor: Mallinckrodt; N=100 ➔ 4; Recruiting ➔ Terminated; Business decision - product discontinued

Clinical • Enrollment change • Trial termination